These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 37548154)

  • 1. Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR
    Abo Al-Hamd MG; Tawfik HO; Abdullah O; Yamaguchi K; Sugiura M; Mehany ABM; El-Hamamsy MH; El-Moselhy TF
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2241674. PubMed ID: 37548154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M).
    Shaheen MA; El-Emam AA; El-Gohary NS
    Bioorg Chem; 2020 Dec; 105():104274. PubMed ID: 33339080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational and Synthetic approach with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S triple mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Burra PVLS; Wakte PS
    Bioorg Chem; 2021 Feb; 107():104612. PubMed ID: 33476869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, apoptotic, and antiproliferative effects of 5-chloro-3- (2-methoxyvinyl)-indole-2-carboxamides and pyrido[3,4-b]indol-1-ones as potent EGFR
    Al-Wahaibi LH; Mohammed AF; Abdel Rahman FES; Abdelrahman MH; Gu X; Trembleau L; Youssif BGM
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2218602. PubMed ID: 37254958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, and Antiproliferative Activity of New 5-Chloro-indole-2-carboxylate and Pyrrolo[3,4-
    Al-Wahaibi LH; Mohammed AF; Abdelrahman MH; Trembleau L; Youssif BGM
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Anticancer Theobromine Derivative Targeting EGFR
    Elkaeed EB; Yousef RG; Elkady H; Alsfouk AA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
    Molecules; 2022 Sep; 27(18):. PubMed ID: 36144596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
    Raghunath Khedkar N; Sindkhedkar M; Joseph A
    Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of new 1
    Gaber AA; Sobhy M; Turky A; Abdulwahab HG; Al-Karmalawy AA; Elhendawy MA; Radwan MM; Elkaeed EB; Ibrahim IM; Elzahabi HSA; Eissa IH
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2283-2303. PubMed ID: 36000168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Free energy perturbation guided Synthesis with Biological Evaluation of Substituted Quinoline derivatives as small molecule L858R/T790M/C797S mutant EGFR inhibitors targeting resistance in Non-Small Cell Lung Cancer (NSCLC).
    Karnik KS; Sarkate AP; Tiwari SV; Azad R; Wakte PS
    Bioorg Chem; 2021 Oct; 115():105226. PubMed ID: 34364055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Synthesis of Non-Covalent Imidazo[1,2-
    Kumar M; Joshi G; Arora S; Singh T; Biswas S; Sharma N; Bhat ZR; Tikoo K; Singh S; Kumar R
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33803355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological evaluation of novel quinoline derivatives as small molecule mutant EGFR inhibitors targeting resistance in NSCLC: In vitro screening and ADME predictions.
    Kardile RA; Sarkate AP; Lokwani DK; Tiwari SV; Azad R; Thopate SR
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114889. PubMed ID: 36375337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and molecular docking studies of novel pomalidomide-based PROTACs as potential anti-cancer agents targeting EGFR
    O Aboelez M; Belal A; Xiang G; Ma X
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1196-1211. PubMed ID: 35470756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis and biological evaluation of novel osimertinib derivatives as reversible EGFR kinase inhibitors.
    Ding S; Gao Z; Hu Z; Qi R; Zheng X; Dong X; Zhang M; Shen J; Long T; Zhu Y; Tian L; Song W; Liu R; Li Y; Sun J; Duan W; Liu J; Chen Y
    Eur J Med Chem; 2022 Aug; 238():114492. PubMed ID: 35696862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Pyrimidine-5-Carbonitriles as potential apoptotic and antiproliferative agents by dual inhibition of EGFR
    Reda N; Mohamed KO; Abdou K; Helwa AA; Elshewy A
    Bioorg Chem; 2024 Apr; 145():107185. PubMed ID: 38350273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.